Milestone Pharmaceuticals (MIST) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Milestone Pharmaceuticals (NASDAQ: MIST) in the last few weeks:

  • 6/4/2019 – Milestone Pharmaceuticals is now covered by analysts at CIBC. They set an “outperform” rating and a $32.00 price target on the stock.
  • 6/4/2019 – Milestone Pharmaceuticals is now covered by analysts at Oppenheimer Holdings Inc.. They set an “outperform” rating and a $32.00 price target on the stock.
  • 6/3/2019 – Milestone Pharmaceuticals is now covered by analysts at Piper Jaffray Companies. They set an “overweight” rating and a $26.50 price target on the stock.
  • 6/3/2019 – Milestone Pharmaceuticals is now covered by analysts at Cowen Inc. They set an “outperform” rating and a $32.00 price target on the stock.
  • 6/3/2019 – Milestone Pharmaceuticals is now covered by analysts at Jefferies Financial Group Inc. They set a “buy” rating and a $28.00 price target on the stock.

Shares of NASDAQ MIST opened at $18.99 on Tuesday. Milestone Pharmaceuticals Inc. has a 12-month low of $15.09 and a 12-month high of $22.13.

In other Milestone Pharmaceuticals news, major shareholder Holdings A/S Novo bought 333,333 shares of the business’s stock in a transaction on Monday, May 13th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $4,999,995.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Rtw Investments, Lp bought 666,667 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $10,000,005.00. The disclosure for this purchase can be found here.

Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.

Read More: What is a balanced fund?

Receive News & Ratings for Milestone Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.